13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
23 檔
17.8%
At the close of Q2 2025, Tri Locum Partners LP disclosed equity holdings valued at approximately $813.2M, spread across 23 reported holdings.
In Q2 2025, Tri Locum Partners LP displayed an active expansion posture, initiating 9 new positions and adding to 11 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, MDGL, ALNY) accounted for 17.8% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 10.41% | -1.21% | +92.92% | |
| 2 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 8.98% | -3.08% | +158.17% | |
| 3 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 8.86% | — | — | |
| 4 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.99% | +1.51% | +167.84% | |
| 5 | ASND | Ascendis Pharma A/S | Stock-Other | 7.73% | -8.20% | EXIT | |
| 6 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.34% | — | +22.97% | |
| 7 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 6.22% | — | — | |
| 8 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 5.88% | — | +89.37% | |
| 9 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 5.74% | — | — | |
| 10 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 5.00% | +5.13% | +55.93% | |
| 11 | EOLS | Evolus Inc | Stock-Other | 3.46% | — | +285.03% | |
| 12 | ABBV | Abbvie Inc | Stock-Healthcare | 3.14% | — | — | |
| 13 | VERA | Vera Therapeutics Inc | Stock-Other | 2.95% | — | +175.03% | |
| 14 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.72% | — | — | |
| 15 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.49% | — | +133.61% | |
| 16 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.18% | +0.05% | — | |
| 17 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.11% | -7.56% | — | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.87% | — | — | |
| 19 | NUVL | Nuvalent Inc-a | Stock-Other | 1.76% | -4.44% | EXIT | |
| 20 | BHVN | Biohaven Ltd. | Stock-Other | 1.16% | — | — | |
| 21 | KRRO | Korro Bio Inc | Stock-Other | 1.06% | — | +8.66% | |
| 22 | WGS | Genedx Holdings CORP | Stock-Other | 0.92% | — | -43.36% | |
| 23 | ✓ | Femasys Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALNY | Alnylam Pharmaceuticals Inc | +8.9% | NEW | New buy |
| 2 | VRNA | Verona Pharma PLC - Adr | +6.2% | NEW | New buy |
| 3 | UNH | Unitedhealth Group Inc | +5.7% | NEW | New buy |
| 4 | ASND | Ascendis Pharma A/S | +5.2% | +356.74% | Add |
| 5 | ABBV | Abbvie Inc | +3.1% | NEW | New buy |
| 6 | ✓ | Avadel Pharmaceuticals PLC ADR | +2.7% | NEW | New buy |
| 7 | ARGX | Argenx Se - Adr | +2.6% | +167.84% | Add |
| 8 | MDGL | Madrigal Pharmaceuticals Inc | +2.5% | +158.17% | Add |
| 9 | TARS | Tarsus Pharmaceuticals Inc | +2.2% | NEW | New buy |
| 10 | ISRG | Intuitive Surgical Inc | +2.1% | NEW | New buy |
| 11 | TEVA | Teva Pharmaceutical-sp Adr | +2% | +92.92% | Add |
| 12 | LEGN | Legend Biotech Corp-adr | +1.9% | NEW | New buy |
| 13 | EOLS | Evolus Inc | +1.5% | +285.03% | Add |
| 14 | BHVN | Biohaven Ltd. | +1.2% | NEW | New buy |
| 15 | VERA | Vera Therapeutics Inc | +1.1% | +175.03% | Add |
| 16 | PRAX | Praxis Precision Medicines I | +0.9% | +133.61% | Add |
| 17 | ✓ | Femasys Inc | 0% | — | Unchanged |
| 18 | KRRO | Korro Bio Inc | -0.1% | +8.66% | Add |
| 19 | INSP | Inspire Medical Systems Inc | -0.6% | +89.37% | Add |
| 20 | AXSM | Axsome Therapeutics Inc | -1.1% | +55.93% | Add |
| 21 | SLNOEUR | Soleno Therapeutics Inc | -1.3% | +22.97% | Add |
| 22 | WGS | Genedx Holdings CORP | -1.7% | -43.36% | Trim |
| 23 | NUVL | Nuvalent Inc-a | -1.7% | -20.72% | Trim |
| 24 | STVN | Stevanato Group S.p.A. | -1.8% | EXIT | Sold out |
| 25 | 2655787D | Blueprint Medicines CORP | -2.3% | EXIT | Sold out |
| 26 | ✓ | Merus N V | -3.4% | EXIT | Sold out |
| 27 | INSM | Insmed Inc | -4% | EXIT | Sold out |
| 28 | ILMN | Illumina Inc | -4.9% | EXIT | Sold out |
| 29 | GILD | Gilead Sciences Inc | -5.1% | EXIT | Sold out |
| 30 | MCK | Mckesson CORP | -9.3% | EXIT | Sold out |
| 31 | CI | THE Cigna Group | -12.5% | EXIT | Sold out |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 23 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ALNY
市值: $29.2M
Top Position Liquidated / Trimmed
CI
前期市值: $24.3M
During Q2 2025, Tri Locum Partners LP's top holdings by market value included TEVA (10.4%)、MDGL (9.0%)、ALNY (8.9%). The largest single position, TEVA, represented 10.4% of total portfolio value.
In Q2 2025, Tri Locum Partners LP made 30 total portfolio adjustments, initiating 9 new buys, adding to 11 positions, trimming 2 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.